首页 | 本学科首页   官方微博 | 高级检索  
     

高原地区慢性阻塞性肺疾病急性加重期合并慢性肺心病抗氧化治疗的研究
引用本文:陈向军,马李杰,侯绍杰,谢永宏,金发光,李志超. 高原地区慢性阻塞性肺疾病急性加重期合并慢性肺心病抗氧化治疗的研究[J]. 中华肺部疾病杂志(电子版), 2013, 6(1): 20-24
作者姓名:陈向军  马李杰  侯绍杰  谢永宏  金发光  李志超
作者单位:第四军医大学唐都医院呼吸内科;第四军医大学病理和病理生理教研室;第四军医大学口腔医学院材料教研室
基金项目:2012年国家自然科学基金面上项目(81270124)
摘    要:目的探讨高原慢性阻塞性肺疾病急性加重期(AECOPD)合并慢性肺心病(CCP)患者抗氧化治疗措施。方法将126例高原(海拔2260~3500m)AECOPD合并CCP患者随机分为红景天治疗组(A组)、氨溴索治疗组(B组)和对照组(C组),每组42例。3组患者均给予抗感染、祛痰、平喘、吸氧等常规治疗。在常规治疗基础上,A组给予口服藏药红景天胶囊,每次2.0g,3次/d,共28d;B组给予盐酸氨溴索30mg静脉滴注,2次/d,共28d。C组仅给予常规治疗。3组均在治疗前和治疗28d后,分别测血清8-异前列腺素F2α(8-iso—PGF2α)、超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)、丙二醛(MDA)、总抗氧化能力(T—AOC)、1s用力呼气容积占预计值百分比(FEV1%pred)、FEV.与用力肺活量比值(FEV1/FVC)、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)。结果治疗前,3组间血清8-iso—PGF2α、SOD、GSH、MDA、T—AOC水平、FEV1%pred、FEV1/FVC、PaO2、PaCO2差异无显著性(均P〉0.05)。治疗后,3组血清8-iso PGF2α、MDA水平、PaCO2较治疗前显著降低(均P〈0.01),SOD、GSH、T—AOC水平、FEV1%pred、FEV1/FVC、PaO2较治疗前显著升高(均P〈0.01);A组和B组各项指标与对照组比较差异均有统计学意义,且A组各项指标均较B组为优(8-iSO—PGF2α:6.21±1.42比8.62±1.45,SOD:89.56±7.61比79.33±7.25,GSH:42.76±4.52比35.26±4.22,MDA:5.26±1.52比7.33±1.68,T—AOC:24.60±3.46比21.67±2.78,FEV1%pred:44.33±6.05比39.84±5.88,FEV1/FVC:47.85±5.36比43.78±5.04,PaO2:53.81±5.60比48.58±5.47,PaCO2:42.82±5.18比47.67±5.54,均P〈0.01)。126例患者治疗前,血清8-iso—PGF2α、MDA与FEV1%pred、FEV1/FVC、PaO:呈显著负相关(分别r=-0.754、-0.788、-0.812和-0.777、-0.654、-0.752,均P〈0.01),与PaCO,呈显著正相关(分别r=0.726、0.685,均P〈0.01),SOD、GSH、T—AOC与FEV1%pred、FEVI/FVC、PaO2呈显著正相关(分别r=0.685、0.716、0.733,0.805、0.746、0.657和0.635、0.702、0.733,均P〈0.01),与PaCO2呈显著负相关(r=-0.716、-803、-0.752,均P〈0.01)。结论氧化/抗氧化比例失衡参与了高原AECOPD合并CCP的发病;红景天和氨溴索在高原AECOPD合并CCP患者的治疗中具有较好的抗氧化作用,红景天的效果优于氨溴索。

关 键 词:肺疾病,慢性阻塞性  肺心病  抗氧化  红景天  氨溴索  高原地区

Protective effect of resveratrol on acute lung injury induce by lipopolysaccharide
CHEN Xiang-jun,MA Li-jie,HOU Shao-jie,XIE Yong-hong,JIN Fa-guang,LI Zhi-chao. Protective effect of resveratrol on acute lung injury induce by lipopolysaccharide[J]. Chinese Journal of lung Disease(Electronic Edition), 2013, 6(1): 20-24
Authors:CHEN Xiang-jun  MA Li-jie  HOU Shao-jie  XIE Yong-hong  JIN Fa-guang  LI Zhi-chao
Affiliation:1 Department of Respiratory Disease,Tangdu Hospital,Fourth Military Medical University,Xi ’ an 710038,China;2 Department of Pathological&Physiopathologic,Fourth Military Medical University,Xi ’an 710032,China;3 Department of Material,School of Stomatology,Fourth Military Medical University,Xi’an 710032,China)
Abstract:Objective To investigate the mechanism and effects of resveratrol protected acute lung injury( ALI) induced by lipopolysaccharide (LPS). Methods Model of ALI in mice was built by LPS intratracheal instillation. Lung tissue was stains with Hematoxylin-eosin to observe the pathological. The Inflammatory cytokines TNF-α, IL-6 was assayed with ELISA in homogenates of lung tissue. Real-time PCR and ELISA were used to detect the expressions of thioredoxinl (Trxl) both in mRNA and protein level. Results In vivo, resveratrol decreased inflammatory cytokines TNF-α, IL-6 in homogenates of lung tissue, at the same time suppressed lung edema, pulmonary alveolar damage. In vitro, resveratrol (50-100 μg/ml, final concentration) could improve cells viability induced by LPS. Furthermore, resveratrol up-regulated expressions of Trxl both protein and mRNA level in vivo and in vitro. Conclusion Resveratrol can protect against ALI induced by LPS, which underlying mechanism may be relationship with up-regulated Trxl expression.
Keywords:Acute lung injury  Resveratrol  Thioredoxinl  Tumor necrosis factor-α  Interleukin-6
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号